1 Ocak 2020 Dergi makalesi Açık Erişim

Cassetta, Luca; Bruderek, Kirsten; Skrzeczynska-Moncznik, Joanna; Osiecka, Oktawia; Hu, Xiaoying; Rundgren, Ida Marie; Lin, Ang; Santegoets, Kim; Horzum, Utku; Godinho-Santos, Ana; Zelinskyy, Gennadiy; Garcia-Tellez, Thalia; Bjelica, Suncica; Taciak, Bartlomiej; Kittang, Astrid Olsnes; Hoeing, Benedikt; Lang, Stephan; Dixon, Michael; Mueller, Verena; Utikal, Jochen Sven; Utikal, Jochen Sven

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Cassetta, Luca</dc:creator>
  <dc:creator>Bruderek, Kirsten</dc:creator>
  <dc:creator>Skrzeczynska-Moncznik, Joanna</dc:creator>
  <dc:creator>Osiecka, Oktawia</dc:creator>
  <dc:creator>Hu, Xiaoying</dc:creator>
  <dc:creator>Rundgren, Ida Marie</dc:creator>
  <dc:creator>Lin, Ang</dc:creator>
  <dc:creator>Santegoets, Kim</dc:creator>
  <dc:creator>Horzum, Utku</dc:creator>
  <dc:creator>Godinho-Santos, Ana</dc:creator>
  <dc:creator>Zelinskyy, Gennadiy</dc:creator>
  <dc:creator>Garcia-Tellez, Thalia</dc:creator>
  <dc:creator>Bjelica, Suncica</dc:creator>
  <dc:creator>Taciak, Bartlomiej</dc:creator>
  <dc:creator>Kittang, Astrid Olsnes</dc:creator>
  <dc:creator>Hoeing, Benedikt</dc:creator>
  <dc:creator>Lang, Stephan</dc:creator>
  <dc:creator>Dixon, Michael</dc:creator>
  <dc:creator>Mueller, Verena</dc:creator>
  <dc:creator>Utikal, Jochen Sven</dc:creator>
  <dc:creator>Utikal, Jochen Sven</dc:creator>
  <dc:date>2020-01-01</dc:date>
  <dc:description>Background Myeloid-derived suppressor cells (MDSC) are a functional myeloid cell subset that includes myeloid cells with immune suppressive properties. The presence of MDSC has been reported in the peripheral blood of patients with several malignant and non-malignant diseases. So far, direct comparison of MDSC across different diseases and Centers is hindered by technical pitfalls and a lack of standardized methodology. To overcome this issue, we formed a network through the COST Action Mye-EUNITER () with the goal to standardize and facilitate the comparative analysis of human circulating MDSC in cancer, inflammation and infection. In this manuscript, we present the results of the multicenter study Mye-EUNITER MDSC Monitoring Initiative, that involved 13 laboratories and compared circulating MDSC subsets across multiple diseases, using a common protocol for the isolation, identification and characterization of these cells.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/5367</dc:identifier>
  <dc:identifier>oai:zenodo.org:5367</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>JOURNAL FOR IMMUNOTHERAPY OF CANCER 8(2)</dc:source>
  <dc:title>Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>